Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Seres Therapeutics, Inc. on June 20, 2017. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 32,385,591 shares were present at the meeting, representing approximately 80.2% of outstanding common stock as of the April 26, 2017 record date. The following proposals were approved:
- Item 1 (Election of Directors): Richard N. Kender and Lorence H. Kim, M.D. were elected as Class II directors to serve until the 2020 Annual Meeting.
- Item 2 (Auditor Ratification): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2017, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Richard N. Kender received 25,676,854 votes FOR, with 1,173,511 votes WITHHELD.
- Lorence H. Kim, M.D. received 25,126,028 votes FOR, with 1,724,337 votes WITHHELD.
- Broker non-votes totaled 5,535,226 for the director elections.
- The auditor ratification received 32,334,687 votes FOR, with only 41,675 votes AGAINST.
- There were zero broker non-votes for the auditor ratification proposal.